Private Banking|Professional Solutions|Investment Management|Investment Banking|About us
Van Lanschot Kempen Logo
  • Solutions
  • Sectors
  • Careers
Jul 2013
Sole Global Coordinator & Joint Bookrunner
€ 26.4 million
Initial Public Offering


Cardio3 BioSciences is a Belgian biotechnology company aiming to heal heart failure

  • Cardio3 BioSciences floated on Euronext Brussels and Euronext Paris
  • Proceeds of the IPO were dedicated to fund European phase III trials of its flagship product, C-Cure
  • Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner

Fully focused on your future

Private Banking

  • Offices
  • Entrepreneurs
  • Healthcare
  • Executives
  • Business professionals
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions

Investment Management

Investment Banking

© Van Lanschot Kempen NV 2023
About us
Security and fraud awareness
Privacy & cookies